LianBio

SHANGHAI, China and PRINCETON, N.J., July 26, 2023 (GLOBE NEWSWIRE) -- LianBio’s (Nasdaq: LIAN) partner, Tarsus Pharmaceuticals (Tarsus), announced yesterday that the U.S. Food and Drug Administration (FDA) approved XDEMVY™ (lotlilaner…

SHANGHAI, China and PRINCETON, N.J., July 12, 2023 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced a…

SHANGHAI, China and PRINCETON, N.J., June 26, 2023 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other Asian markets, today announced that CAMZYOS®…

•  LIBRA 临床试验旨在支持TP-03在中国的注册审批•  该临床试验的顶线结果预计将于2023年第四季度出炉 上海和新泽西州普林斯顿, June 08, 2023 (GLOBE NEWSWIRE) -- 联拓生物(纳斯达克:LIAN)，一家致力于为中国和其他亚洲主要市场的患者带来创新药物的生物技术公司，于今日宣布在中国蠕形螨睑缘炎患者中开展的 TP-03 LIBRA III期临床试验已完成所有受试者入组。…

<!-- Name:DistributionId Value:8836929 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False --> <!-- Name:IcbCode Value:4573 -->…

<!-- Name:DistributionId Value:8825727 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False --> <!-- Name:IcbCode Value:4573 -->…

SHANGHAI, China and PRINCETON, N.J., Nov. 09, 2022 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced the…

•   LIBRA trial designed to support registration in China•   Topline results expected in the fourth quarter of 2023 SHANGHAI and PRINCETON, N.J., Nov. 01, 2022 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company…

Completed enrollment in China Phase 3 trial of mavacamten; topline data expected mid-2023 Submitted mavacamten New Drug Application (NDA) in Singapore Submitted infigratinib NDA in Hong Kong Three additional registration-enabling programs…

SHANGHAI and PRINCETON, N.J., April 29, 2022 (GLOBE NEWSWIRE) -- LianBio’s (Nasdaq: LIAN) partner, Bristol Myers Squibb, announced yesterday that the U.S. Food and Drug Administration (FDA) approved Camzyos™ (mavacamten, 2.5 mg, 5 mg, 10…